Aug 23,2018

FDA grants digital therapeutic for Alzheimer's symptoms Breakthrough Device designation

Dthera Sciences, a San Diego-based developer of clinical and consumer digital therapeutics for individuals with neurodegenerative conditions, announced today that its development stage intervention, DTHR-ALZ, has been granted Breakthrough Device designation by the FDA. DTHR-ALZ is a digital intervention “intended to mitigate the symptoms of agitation and depression associated with major neurocognitive disorder of the Alzheimer’s type,” according to the current proposed indication for use.

REGULATORY FDA

#software

#mobile app

View Analyst & Ambassador Comments
Go to original news
Aug 27,2018

Cognoa Demonstrates Advances of its AI-Based Technology for Identifying Autism in Children

Cognoa, a digital behavioral health company, today announces results from a clinical study of its second-generation AI based algorithms which demonstrates accuracy improvements over its first-generation screening algorithm in supporting the diagnosis of autism spectrum disorder (ASD) in young children. Two algorithms are trained to identify autism, one based on short, structured parent-reported questionnaires and the other on tagging key behaviors from short, semi-structured home videos of children. A combination algorithm is then used to combine the results into a single assessment of higher accuracy. A multi-center clinical study of n = 162 children is performed to ascertain the performance of these algorithms and their combination.

CLINICAL STUDY

#software

View Analyst & Ambassador Comments
Go to original news
Jan 09,2018

Voluntis and WellDoc announce partnership to combine diabetes digital therapeutic offerings

Voluntis and WellDoc®, two of the industry’s leading digital therapeutics companies, announced today a commercial agreement aimed at combining Voluntis’ insulin titration technology with WellDoc’s extensive digital coaching platform to create a holistic digital diabetes management solution for patients, providers, health systems and health plans. Voluntis developed Insulia®, an FDA-cleared, prescription-only digital companion for people and their care teams using basal insulin to treat type 2 diabetes. It provides automated basal insulin dose recommendations for people with type 2 diabetes while enabling the health care team to remotely monitor progress.

COLLABORATION PARTNERSHIP

#product & service

#software

#coaching

View Analyst & Ambassador Comments
Go to original news
Jan 11,2018

Brain Games: How thoughtfully designed tech is addressing cognitive health

New therapeutics and devices have shown evidence of repairing damaged nerve passageways, overcoming cognitive disorders, and simply fine-tuning the healthy brain, so it’s no surprise that innovators are rushing to bring these technologies into the mainstream. Several new technologies, such as VR, create powerful experiences for users, and new experiences are key to brain plasticity, Dr. Adam Gazzaley, founder and executive director of the Neuroscape Lab at UCSF, cofounder of Akili Interactive Labs and Jazz Venture Partners explained.This technology and approach has since become the heart of Akili Interactive Labs’ Project: Evo.

PRODUCT

#virtual reality

#software

View Analyst & Ambassador Comments
Go to original news
Feb 14,2018

Click Therapeutics Announces the Release of the Click Affective Pictures Set (CAPS) to Researchers Globally

Click Therapeutics, Inc. (Click), a leader in Digital Therapeutics™ solutions, announces the release of the Click Affective Pictures Set (CAPS). The CAPS is a set of 109 professionally developed and validated images of facial affect, which includes 20 faces expressing six core emotions (happy, sad, surprised, afraid, angry and disgusted) and neutral expressions. Eighty-two emotion gradients, in which each individual emotion expression is morphed from 100% intensity to 10% intensity, in 10% increments, are also included in the CAPS. The CAPS images will be utilized in Click’s products, and will be free for academic researchers to download for use in neuroscience, psychology, psychiatry and related fields of research.

PRODUCT

#software

View Analyst & Ambassador Comments
Go to original news
Feb 21,2018

FDA recognizes Cognoa's child development app as autism diagnostic

Palo Alto, California-based Cognoa’s machine learning app for pediatric behavioral health has received categorization from the FDA as a diagnostic medical device for autism, according to an announcement from the company. By analyzing parent-provided information and videos of a child’s natural behavior, the company’s app uses machine learning to provide an assessment of whether that child is developing at the right pace, as well as to evaluate their behavioral health.

REGULATORY FDA

#software

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 06,2018

Click Therapeutics Announces Multiple Publications Supporting Its Digital Therapeutic for Major Depressive Disorder

Click Therapeutics announces today multiple publications and presentations of clinical research data supporting its digital therapeutic for major depressive disorder (MDD). The results of a 51-person randomized controlled trial of the Emotional Faces Memory Task (EFMT), a digital therapeutic for MDD, were recently published in npj Digital Medicine, a Nature research journal. This trial found EFMT to be superior to the control group in terms of MDD symptom reduction, and also the proportion of participants meeting “clinical responder” criteria.

CLINICAL STUDY

#software

#pdt

View Analyst & Ambassador Comments
Go to original news
Jun 20,2018

Voluntis and Monarch Medical Technologies Announce Partnership to Provide Seamless Solution for Insulin Dosing Across the Continuum of Care

Voluntis and Monarch Medical Technologies, the leader in precision insulin dosing for optimized inpatient glucose management, today announced a new strategic partnership aimed at improving the coordination of glycemic management for patients with insulin dosing recommendations in both the inpatient and outpatient setting. The partnership between the two companies supports adherence to insulin dosing regimens grounded in evidence-based standards of care throughout all care settings. Within the hospital, the use of EndoTool by Monarch Medical has been shown to significantly reduce hypoglycemia rates, among other patient outcomes, and Insulia has been shown to effectively support diabetes management with automated basal insulin dose recommendation and personal coaching messages in the outpatient setting.

COLLABORATION PARTNERSHIP

#connected device

#mobile app

#software

View Analyst & Ambassador Comments
Go to original news
Sep 11,2018

Your smartphone as medicine: Digital therapy is here to stay

The FDA recently approved the first prescription digital therapy, Pear’s Reset app and program, which is focused on substance abuse. Others are likely to follow. That means your next trip to the doctor could include a prescription for a mobile app in addition to, or instead of, medicine. A growing body of research on digital therapies is validating what physicians have long known: that environment and behavior play substantial roles in most preventable diseases, and that software-based digital therapy can consistently and positively influence both.

#mobile app

#pdt

#software

View Analyst & Ambassador Comments
Go to original news
Sep 12,2018

Akili, University of California's new licensing agreement marries physical activity with digital cognitive dysfunction therapy

Digital therapeutics maker Akili Interactive Labs today announced a deal with the University of California’s governing board concerning exclusive licensing of a new technology that will combine the company’s focus on neural systems with physical activity. Developed at the Neuroscape Lab at UCSF, the tech follows in the footsteps of Akili’s other efforts in that it is primarily delivered through a video game interface. By employing an additional motion-capture interface, however, it challenges users to maintain cognitive control while performing physical movements that are accounted for in game. According to the announcement, the technology is currently being evaluated in multiple clinical trials. Akili said that it believes this dual-faceted approach could expand its capacity to provide cognitive dysfunction treatment to patients with a range of conditions.

COLLABORATION PARTNERSHIP

#r&d

#mobile app

#software

View Analyst & Ambassador Comments
Go to original news
Subscribe to SOFTWARE